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Abstract
Smooth muscle cells are of key importance for the proper functioning of different visceral organs including those of the
urogenital system. In the mouse ureter, the two transcriptional regulators TSHZ3 and SOX9 are independently required for
initiation of smooth muscle differentiation from uncommitted mesenchymal precursor cells. However, it has remained
unclear whether TSHZ3 and SOX9 act independently or as part of a larger regulatory network. Here, we set out to
characterize the molecular function of TSHZ3 in the differentiation of the ureteric mesenchyme. Using a yeast-two-hybrid
screen, we identified SOX9 as an interacting protein. We show that TSHZ3 also binds to the master regulator of the smooth
muscle program, MYOCD, and displaces it from the coregulator SRF, thereby disrupting the activation of smooth muscle
specific genes. We found that the initiation of the expression of smooth muscle specific genes in MYOCD-positive ureteric
mesenchyme coincides with the down regulation of Sox9 expression, identifying SOX9 as a possible negative regulator of
smooth muscle cell differentiation. To test this hypothesis, we prolonged the expression of Sox9 in the ureteric mesenchyme
in vivo. We found that Sox9 does not affect Myocd expression but significantly reduces the expression of MYOCD/SRF-
dependent smooth muscle genes, suggesting that down-regulation of Sox9 is a prerequisite for MYOCD activity. We
propose that the dynamic expression of Sox9 and the interaction between TSHZ3, SOX9 and MYOCD provide a mechanism
that regulates the pace of progression of the myogenic program in the ureter.
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Introduction
Smooth muscle (SM) is a frequent investment of visceral organs,
and is required to assure their rigidity and contractility. In the
urinary tract, SM is present in the renal pelvis, the ureter, the
bladder and the urethra and plays a crucial role in the functional
and structural integrity of these organs.
In vivo characterization of visceral smooth muscle cell (SMC)
development in the ureter has provided evidence for a role for
Sonic hedgehog (SHH) and Bone morphogenetic protein 4
(BMP4) signaling in the differentiation of the mesenchymal cells
that surround the urothelium [1,2,3,4,5,6,7,8]. Targeted removal
of Shh signal production in the ureteric epithelium resulted in a
reduction of ureteral mesenchymal cell proliferation and delayed
SM differentiation, which is likely to play a causal role in the
observed hydroureter [8]. Moreover, removal of Shh resulted in a
deficit of Bmp4-expressing peri-ureteral mesenchyme, while
conditional deletion of Bmp4 dramatically reduced expression of
SM specific genes [1,8]. Four transcription factors, the T-box
protein TBX18, the zinc-finger protein Teashirt 3 (TSHZ3), the
homeodomain-containing protein SIX1 and the high-mobility-
group (HMG) domain transcription factor SOX9 are expressed in
SMC precursors and are important for the cytodifferentiation of
ureteric mesenchyme [9,10,11,12]. Phenotypic and molecular
analyses of Tbx18 mutant ureters have indicated that Tbx18 is
required for specifying mesenchymal cell precursors to a ureteric
fate [9]. Six1 acts synergistically with Tbx18 in regulating the
proliferation and differentiation of SMC precursors [12]. Teashirt
3 (Tshz3) is expressed in precursors, and in differentiating and
differentiated SMCs; its expression is maintained in adult ureteric
SM. In Tshz3 mutant ureters the myogenic program is not
activated in the proximal region due to the absence of expression
of myocardin (Myocd), a key regulator of SM differentiation [11,13].
It was suggested that SM differentiation depends on a signaling
axis starting with secreted SHH and ending with ureteric SMC
differentiation, with Tszh3 downstream of Bmp4 but upstream of
Myocd and SMC contractile protein synthesis [11,14]. This work
also provided some indication concerning the temporal control of
SMC differentiation. In the wild type ureter, MYOCD and SMC
markers are detected at E15.5, shortly before onset of urine
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production at E16.0 to E16.5. Tshz32/2 mice as well as other
mutants with defects in ureteric SM differentiation consequently
develop hydroureter at around E16.5 [11]. Recently, it was shown
that the high mobility group domain transcription factor gene Sox9
plays an important role both in kidney and ureter development in
the mouse [10,15]. Sox9 is transiently expressed in the undiffer-
entiated ureteric mesenchyme. Conditional inactivation of Sox9 in
this domain led to a significant down-regulation of Myocd
expression and perturbed differentiation into SMC, which resulted
in strong proximal hydroureter formation due to functional
obstruction. The involvement of visceral SMCs in pelvi-ureteric
junction obstruction (PUJO), a frequent cause for persisting
dilatation of the upper urinary tract (hydronephrosis), underlies
the significant interest in understanding the mechanisms that
control the differentiation of visceral SMCs [16,17,18,19].
Previous data suggested that both TSHZ3 and SOX9 critically
regulate the onset of the myogenic program in the developing
ureter. However it is not clear whether TSHZ3 and SOX9 act
independently or are part of a regulatory network that controls
cytodifferentiation of the ureteric mesenchyme. Here, we set out to
characterize the molecular function of TSHZ3 in the development
of the ureteric mesenchyme. Using a yeast-two-hybrid screen, we
identified SOX9 as an interacting protein. We verify this
interaction in vitro and in vivo, and define its temporal nature in
the ureter. We show that TSHZ3 also binds to MYOCD, and that
the ternary complex between SOX9, TSHZ3 and MYOCD
disrupts the activation of SM specific genes. Therefore, despite
controlling the onset of the myogenic program by inducing the
expression of Myocd, TSHZ3 and SOX9 subsequently delay the
differentiation of visceral SMCs by inhibiting Myocardin activity.
We therefore propose that the dynamic expression of Sox9 and the
interaction between TSHZ3, SOX9 and MYOCD provide a
mechanism that regulates the pace of progression of the myogenic
program in the ureter.
Materials and Methods
Ethics Statement
All experiments were performed in accordance with the
European legislation (86/609/CEE), the guidelines established
by the French Ministry of Agriculture (Animal Rights Division)
and approved by H. Hedrich, state head of the animal facility at
Medizinische Hochschule Hannover and performed according to
German legislation. The architecture and functioning rules of our
animal house, as well as our experimental procedures have been
approved by the ‘‘Direction De´partementale des Services Ve´te´r-
inaires’’ (ID number E-13-055-21). Experiments were not
performed on living animals.
Mouse strains
Wild–type and Tshz3lacZ mouse lines used in this study were
maintained on a CD1 outbred background. The Tshz3lacZ allele
carries an in-frame insertion of lacZ coding sequence within the
second exon of Tshz3 [11]. For conditional prolonged Sox9
expression, females homozygous for an HprtSox9-allele were crossed
with Tbx18Cre/+ males as previously described [10].
Cell lines
The murine C3H10T1/2 cell line was purchased from
American Type Culture Collection (ATCC number CCL-226);
the human HEK293T cell line was a gift from Dr. J. Iovanna
(CRCM, Marseille, France). Cell lines were cultivated following
the ATCC culture protocol and maintained in Dulbecco’s
Modified Eagle’s Medium with supplement of 10% fetal bovine
serum and 50 units/ml penicillin, 50 mg/ml streptomycin, 1%
sodium pyruvate.
Yeast Two-hybrid Screen (Y2H)
The screen has been previously reported in [20].
Immunological and in situ hybridization analysis
Tissues were fixed in 4% paraformaldehyde/PBS. Immuno-
staining was performed either on 10 mm cryosections of tissues or
on paraffin embedded sections after quenching endogenous
peroxidase activity and antigen retrieval followed by reaction
with secondary antibodies. Primary and secondary antibodies used
were mouse anti-smooth muscle a actin (SMaA, 1A4, Sigma; 1/
1000), guinea-pig anti-TSHZ3 antibody (1/5000) produced by A.
Garratt’s laboratory (Max-Delbrueck-Center, Berlin, Germany).
Rabbit anti-SOX9 antibody (1/1000) was kindly provided by Dr
Pascal de Santa Barbara (Inserm, ERI25, Montpellier, France).
Other primary antibodies were rabbit anti-b-galactosidase (Cap-
pel, 1/500), mouse anti-b-galactosidase (Sigma Aldrich, 1/1000),
goat anti-MYOCD (sc-21559, Santa-Cruz, 1/200), rat anti-HA
(3F10 Roche, 1/1000), mouse anti-Flag M2 (F3165, Sigma
Aldrich, 1/1000). Secondary antibodies used were Alexa-Fluor-
546 or 488 donkey anti-rabbit, Alexa-Fluor-546 or 488-IgG1 goat
anti-mouse, Alexa-Fluor-488 goat anti-guinea pig and Alexa-
Fluor-555 goat anti-rat (Molecular Probes). Secondary antibodies
were diluted at [1/1000]. Cultured cells were fixed in 1% PFA for
10 min. Cryosections and cultured cells were washed with 0.1%
Tween/PBS for 15 min and then blocked in 10% foetal calf
serum, 0.1% Tween/PBS for 1 hour. Fixed samples were
incubated with primary antibodies overnight at 4uC, followed by
incubation with secondary antibodies for 1 hour (RT) and then
counterstained with DAPI.
In situ hybridisation using digoxigenin-labeled probes was
performed on sections as previously described [21]. The Myocd
probe was kindly provided by Dr Eric Olson (University of Texas
Southwestern Medical Center, Dallas, USA).
Construction of plasmids
The mouse Myocd 856-Flag pcDNA3.1 (smooth muscle
Myocardin isoform, [22]) was kindly provided by Dr Joseph Miano
(Aab Cardiovascular Research Institute, University of Rochester,
USA). The human Sox9-Flag expression vector was provided by
Dr Andreas Schedl (U638, Inserm, Nice, France). The Flag-
Sox9DC pcDNA3.1 was given by Dr Benoit de Crombrugghe
(University of Texas M. D. Anderson Cancer Center, Houston,
USA). The mouse mammalian expression plasmid for serum
response factor (Srf) was given by Dr Zhenlin Li (University Pierre
and Marie Curie, Paris VII, France). The mouse Myod 856-HA,
Srf-HA, Sox9-HA, and Flag-Sox9HMG were generated by PCR
amplification and cloned into pcDNA3.1. The pcDNA3.1-HA-
Tshz3 and pCX-Tshz3 clones were produced by subcloning a
3.4 kbp PCR-generated fragment covering the complete HA-
Tshz3 open reading frame into the pcDNA3.1(+) (Invitrogen) and
the pCX-MCS2 (gift of Dr Xavier Morin, ENS, Paris, France)
plasmids, respectively. An N-terminal 6XHis tag was ligated to
Tshz3 by PCR. N-Tshz3 and C-Tshz3 were cloned by PCR and
ligated to pcDNA3.1. Human TSHZ3-trunc pCMV was a gift
from Pr Joseph D. Buxbaum (Laboratory of Molecular Neuro-
psychiatry, Mount Sinai School of Medicine, New York, USA).
Tshz3-trunc was cloned into the pcDNA3.1 vector in frame with
an amino-terminal HA epitope. HA-Tshz3 dZNF was initially
generated in pBS SK vector by a QuikChange multi-site
mutagenesis kit (Stratagene) and then transferred to the pcDNA3.1
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vector. All the resulting plasmids were sequenced to check the
insert integrity.
mRNAs extraction and qRT-PCR
Before qRT-PCR analysis on cells, C3H10T1/2 cells were
nucleofected using AmaxaTM nucleofector Kit V (Lonza) following
the manufacturer’s protocols with designed program T-020. For
qRT-PCR on ureters, embryonic ureters were dissected from
E16.5 Tbx18Cre/+HprtSox9/+ and wild type embryos. Total RNA was
isolated using TRIsure Reagent (Bioline) according to the
manufacturer’s instructions. RNA was treated with RQ1 RNase-
free DNase1 (Promega). 750 ng of total RNA was reverse-
transcribed using Superscript II reverse transcriptase (Invitrogen)
with oligo dT(12–18mers) and random primers (15mers). cDNA
was submitted to RNAseH treatment during 209 at 37uC to
remove the complementary RNA strand. Real-time PCR was
performed on an IQ5 System (Bio-Rad Laboratories) using SYBR
Green Supermix (Invitrogen). qRT-PCR was performed for
40 cycles of 95uC for 30 s, 60uC for 30 s, and 72uC for 30 s.
Analyses were performed in triplicate on RNA samples from
several independent experiments. Results were normalised to
Gadph housekeeping gene [23] and then normalised to their
respective control group. RQ=22DDCt and DDCt= (Ct experimental
– Ct Gadph) – (Ct control – Ct Gadph).
Primer sequences used for Sybr qRT-PCR are as follows:
Mouse Tshz3 S-GCGCGCAGCAGCCTATGTTTC and
AS-TCAGCCATCCGGTCACTCGTC;
Mouse Myocd S-CGGATTCGAAGCTGTTGTCTT and
AS-AAACCAGGCCCCCTCCC;
Human Sox9 S-AACGCCTTCATGGTGTGG and
AS-TCGCTCTCGTTCAGAAGTCTC;
Mouse Sox9 S- CGAACGCACATCAAGACGG and
Figure 1. TSHZ3 and SOX9 physically interact in vitro and in vivo. (A–I) Mapping of the TSHZ3 interaction domain with SOX9. (A) Sequence
analysis of the two Sox9 clones clA47 (amino acids 1–163) and clA45 (amino acids 1–168) showed that the selected interaction domain corresponds to
amino acids 1 to 163 of SOX9 that contains part of the HMG domain. The SOX9DC construct contains the HMG domain but not the transactivation
(TA) domain (B) Coimmunoprecipitation experiment shows SOX9DC interacting with TSHZ3 protein. (C) Schematic structure of the TSHZ3 full length
(TSHZ3 fl) and TSHZ3 truncated proteins used in this study. N-TSHZ3 harbours the N-terminal half of TSHZ3 (amino acid: 1–483), C-TSHZ3 harbours
the C-terminal half of TSHZ3 (amino acid: 484–1081), TSHZ3 dZNF arbours N-terminal half of TSHZ3 (amino acid: 1–483) and mutated zinc finger
motifs and, TSHZ3-trunc lacks the amino acids 1–182. AD = acidic domain; Znf = zinc finger domain; HD = homeodomain. (D) GST pulldown assays
show that TSHZ3 interacts with in vitro translated SOX9. (E) TSHZ3-HA, N-TSHZ3-HA and SOX9-Flag localize to the nucleus in HEK293T transfected
cells. Cells were counterstained with DAPI to detect nuclei. (F–I) HEK293T cells were transfected with HA-tagged TSHZ3 constructs and Flag-tagged
SOX9 or control empty plasmids. Proteins were immunoprecipitated with a Flag antibody, followed by immunoblotting as indicated; in: input.
doi:10.1371/journal.pone.0063721.g001
Figure 2. Comparative expression analysis of SOX9 and TSHZ3 in the developing ureter. (A–I) Immunostainings for SOX9 (red), TSHZ3
(green) on sagittal sections at E12.5, and on transverse sections of the ureter at E14.5 and E15.5. Nuclei were stained with DAPI (blue). (A, D, G) TSHZ3
antibody staining reveals mesenchymal expression in the ureter. (B, E, H) SOX9 antibody staining reveals a highly dynamic expression pattern in the
developing ureter. (C, F, I) SOX9 expression overlaps with that of TSHZ3 in undifferentiated mesenchymal precursors from early stages whereas SOX9
signal decreases from E15.5 in the cm of the ureter. Broken line in A, B, C, D, E, G, H delineates metanephric mesenchyme (mm), ureter (ur), ureteric
epithelium (ue), condensed ureteric mesenchyme (cm), loose ureteric mesenchyme (lm).
doi:10.1371/journal.pone.0063721.g002
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AS- CGGCTGCGTGACTGTAGTAGG;
Mouse SMaA S-CGCTGTCAGGAACCCTGAGA and
AS-CGAAGCCGGCCTTACAGA;
Mouse SMMHC S-TGGACACCATGTCAGGGAAA and
AS-ATGGACACAAGTGCTAAGCAGTCT;
Mouse telokin S-GACACCGCCTGAGTCCAACCTCCG
and
AS-GACCCTGTTGAAGATTTCCTGCCACTG;
Mouse SM22 S-AGCCAGTGAAGGTGCCTGAGAAC and
AS-TGCCCAAAGCCATTAGAGTCCTC.
GST protein-binding assays
pGEX plasmids encoding a GST fusion with TSHZ3 full length
(TSHZ3fl), truncated TSHZ3 (N-TSHZ3, C-TSHZ3), SOX9 full
length (Dr Pascal de Santa Barbara, Inserm, ERI25, Montpellier,
France), MYOCD full length protein (gift from Dr Eric N Olson,
University of Texas Southwestern Medical Center, Dallas, USA)
were transformed into E. coli BL21. GST fusion proteins were
isolated from cell lysates using standard protocols. The production
of GST fusion proteins was induced by a 4-hour induction with
0.1 M IPTG at 25uC. Bacteria were lysed in STE (150 mM NaCl,
10 mM Tris pH 8, 1 mM EDTA), 1 mM DTT and 50 mg
lysozyme, 1% Triton X-100. Resin-bound GST fusion proteins
were pelleted, washed in the same buffer containing 0.5% Triton
X-100. Tshz3fl, N-Tshz3, C-Tshz3, Sox9 and Myocd were translated
in vitro in presence of (35S) methionine. Glutathione beads
conjugated with GST fusion protein pre-incubated in 1% BSA
were incubated overnight at 4uC with radiolabeled proteins.
Proteins were analyzed by SDS-polyacrylamide gel electrophoresis
(PAGE) and subsequent autoradiography.
Coimmunoprecipitation assays and Western blot
HEK293T cells were transiently transfected with plasmids
encoding the Flag or HA-tagged MYOCD, HA-tagged TSHZ3,
Flag-tagged SOX9, HA-SRF with Promofectin (Promocell).
pcDNA3.1 parental plasmid was transfected to equalize the
amount of DNA in each condition. For protein isolation, after
24 hours of culture, 100 mm plates of cells were scraped into 1 ml
of PBS and centrifuged at 2000 rpm for 5 min. The cell pellet was
immediately resuspended in 500 ml of lysis buffer containing
50 mM Tris-HCl pH 7.6, 200 mM NaCl, 1 mM EDTA, 0.25%
Na-deoxycholate, 1 mM PMSF, 1 mM Na3VO4 and protease
inhibitors (Complete; Roche). Cell extracts were incubated with
anti-Flag agarose M2 beads (Sigma) or anti-HA (3F10, Roche) and
protein G beads prewashed in lysis buffer according to the
manufacturer’s protocol. Samples were incubated overnight at
4uC on a rotator. For Western blot, total cellular protein was
subjected to SDS/8% PAGE and then transferred to nylon
membranes. 4% total extract was loaded as input. Immunoblot-
ting was carried out using rat anti-HA (3F10, Roche) or mouse
anti-Flag M2 (F1804, Sigma) antibodies, followed by secondary
anti-rat HRP (Molecular Probes) or anti Mouse TrueBlotH
ULTRA HRP (eBioscience) antibodies and detection using the
Western Lightning plusTM ECL (Perkin Elmer).
Mammalian expression and reporter gene assays
The mouse telokin promoter – luciferase reporter gene including
nucleotides from 2190 to + 181 (T370, telokin-Luc) of the telokin
gene was a gift from Dr Paul Herring (Indiana University School
of Medicine, Indianapolis, USA). The rat SM a-actin promoter
fragment extends from nucleotide 2,555 to 2,813 and the rabbit
SMMHC promoter from 4,200 to 11,600, the SM22–luciferase
reporter gene includes nucleotides 475 to 61 of mouse SM22 were
generously provided by Pr Gary Owens (Molecular Physiology
and Biological Physics, University of Virginia, USA). Plasmids
were transfected into mouse C3H10T1/2 fibroblasts cells using
FuGENE6 (Roche). 10T1/2 cells were seeded at 25000 cells/well
in 24-well plates. Half an hour post-seeding, each dish was
incubated with a total of 1 mg of plasmid DNA (0.125 mg of
promoter-luciferase plasmid, 0.25 mg of expression plasmid, and
0.025 mg of phRLTK plasmid as an internal control) and 2 ml of
FuGENE in 45 ml of Dulbecco’s modified Eagle’s medium. 24 h
later, extracts (100 ml/well) were prepared for measurement of
luciferase activity with Tristar LB941 multiplate reader (Berthold
Technologies). The level of promoter activity was evaluated by
determining the level of firefly luciferase activity relative to the
control Renilla using the dual luciferase assay system essentially as
described by the manufacturer (Promega). Results are reported as
the mean and SEM.
Figure 3. Expression of SOX9 in SM progenitors. (A–G) Transverse
tissue sections of E14.5 (A–C) and E15.5 (E–G) proximal ureters showing
co-immunostaining of SOX9 (red) and MYOCD (green) in the condensed
mesenchyme at E14.5. (D, H) Smooth muscle a actin (SMaA, magenta)
immunostaining is absent in E14.5 ureteric tissue section but is
markedly expanded in the condensed mesenchymal compartment at
E15.5.
doi:10.1371/journal.pone.0063721.g003
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Figure 4. TSHZ3 and SOX9 modulate the transcriptional and myogenic activity of Myocardin. (A) Overexpression of Sox9 and Tshz3
suppresses the induction of endogenous SM gene expression by MYOCD. 10T1/2 cells were cotransfected with indicated combination of expression
constructs. Cells were harvested 24 hours post nucleofection for qRT-PCR analysis of transcripts of endogenous SMaA, telokin, SMMHC and SM22a?
Gadph was used to normalize (n = 6, mean 6 S.EM). (B) SOX9 and TSHZ3 suppress the MYOCD and SRF-induced activation of SM specific promoters.
10T1/2 cells were cotransfected with indicated combination of expression constructs, luciferase reporters controlled by SMaA, telokin, SMMHC and
SM22a? The amount of each plasmid was 250 ng for Myocd, Sox9 and Tshz3, 10 ng for Srf, 125 ng for promoter reporter plasmid and 25 ng for
PhRLTK renilla luciferase (n = 8, mean 6 S.EM). Asterisk indicates statistical significance as determined by a Wilcoxon test (p,0.05).
doi:10.1371/journal.pone.0063721.g004
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Statistical analyses
Statistical analyses were carried out using StatEL software for
Mac OSX (www.adscience.eu). The non parametric Wilcoxon test
was used to evaluate the significance of differences between control
and tested samples. In all these analyses, P,0.05 or P,0.01 were
regarded as significant.
Results
TSHZ3 and SOX9 form a molecular complex
We recently reported on the important role of the transcription
factor TSHZ3 for ureteric SM differentiation [11], but the
molecular function of TSHZ3 in this developmental context
remained unclear. Data obtained in invertebrate and vertebrate
models showed that TSHZ-mediated gene regulation depends on
interaction with different protein binding partners [24,25,26,27].
To get insight into the molecular function of TSHZ3, we searched
for protein interaction partners using a yeast-2-hybrid screen [20].
We identified 84 independent clones among which 47 (56%)
clones encode for high mobility group (HMG) containing proteins,
corresponding to SMARCE1/BAF57 (40 clones) [20] and five
SOX proteins (7 clones). Sequence analysis of the 47 clones
revealed that the selected interaction region contained an HMG
domain. Two of the cDNAs (cl A47 and cl A45; Figure 1A) coded
for SOX9 (Genbank accession number NM_011448.3), which has
been implicated in SMC differentiation in the proximal ureter
[10]. Consistent with the yeast two-hybrid data, co-immunopre-
cipitation assays performed in HEK293T cells using HA-epitope
tagged TSHZ3 and Flag-epitope tagged N-terminal SOX9 (Sox9
DC; Figure 1A) showed that a fragment of SOX9 containing the
HMG domain interacts with TSHZ3 (Figure 1B).
To delineate the region of TSHZ3 that accounts for SOX9
binding, we generated various Tshz3 deletion constructs
(Figure 1C) and performed a series of in vitro and in vivo binding
assays (Figure 1D, F–I). We found that in vitro translated SOX9
binds to a fusion protein of full-length TSHZ3 (TSHZ3fl) with
GST (GST-TSHZ3fl) but not to GST alone (Figure 1D). In a
reciprocal manner, TSHZ3fl bound to GST-SOX9 fusion protein
(Figure S1A). In these assays, SOX9 strongly interacted with
GST-N-TSHZ3 harbouring the N-terminal half of TSHZ3
(amino acid: 1–483; N-TSHZ3) and weakly with the C-terminal
half of TSHZ3 (amino acid: 484–1081; C-TSHZ3) (Figure 1D); N-
Figure 5. TSHZ3 and MYOCD physically interact in vitro and in vivo. (A–E) Mapping of the TSHZ3 interaction domain with MYOCD. (A) GST
pulldown assays show TSHZ3 constructs interacting with in vitro translated MYOCD. (B–E) HEK293T cells transfected with HA-tagged TSHZ3
constructs and Flag-tagged MYOCD or control empty plasmids and then immunoprecipitated with a Flag antibody, followed by immunoblotting as
indicated; in: input. (G) 10T1/2 cells were cotransfected with a luciferase reporter controlled by the telokin promoter and TSHZ3 constructs. TSHZ3-
trunc-HA lost the ability to suppress the transcriptional activity of MYOCD/SRF (n = 8, mean 6 SEM). Asterisk indicates statistical significance as
determined by a Wilcoxon test (p,0.05).
doi:10.1371/journal.pone.0063721.g005
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TSHZ3 interacted with GST-SOX9 (Figure S1A). Next we
performed coimmunoprecipitation (co-IP) assays in HEK293T
cells transfected with a HA-tagged TSHZ3 construct alone, or in
the presence of Flag-tagged SOX9. Tagged versions of both
SOX9 and TSHZ3 localized to the nucleus of HEK cells
(Figure 1E). An enrichment of HA-tagged TSHZ3 protein was
detected only upon co-transfection of the Sox9 expression construct
(Figure 1F). The specificity of the association was confirmed by
performing reciprocal co-IP assay with anti-HA antibody (Figur-
e S1B). Co-IP assays confirmed that N-TSHZ3 interacts with
SOX9 in vivo (Figure 1G) and showed that the zinc finger motif
was dispensable for interaction (Figure 1H). The N-terminal
deletion mutant of TSHZ3 (amino acid: 183–1081; TSHZ3-trunc)
did not interact with SOX9 (Figure 1I). These data demonstrate
that the interaction with SOX9 takes place within the first 182
amino acids of the TSHZ3 protein.
SOX9 and TSHZ3 show overlapping expression in SM
progenitors of the developing ureter
Genetic and molecular studies suggested that Tshz3 and Sox9
are required for the cytodifferentiation of the proximal ureteric
mesenchyme into SM [10,11]. These data together with our in vitro
binding studies suggested that TSHZ3 and SOX9 interact
molecularly in ureteric mesenchymal cells in vivo. To determine
when this interaction takes place in the developing ureter, we
performed a detailed analysis of the expression of TSHZ3 and
SOX9 from E12.5 to E16.5 in wild-type (WT) ureters. From E12.5
to E14.5, TSHZ3 (Figure 2A, D) and SOX9 (Figure 2B, E) were
co-expressed (Figure 2C, F) in the condensed mesenchyme (cm)
around the epithelium (ue) as well in the outer ring of loose
mesenchymal cells (lm). SOX9 was also detected in the epithelium,
until E14.5 (Figure 2E). From E15.5 onwards, SOX9 expression
was down-regulated in the condensed mesenchyme (Figure 2H, I)
that undergoes SM differentiation [8,28].
Downregulation of SOX9 coincides with the activation of
the expression of MYOCD target genes
The decrease of SOX9 protein at the onset of SMC
differentiation prompted us to compare the expression of SOX9
with that of SM markers and MYOCD, a key transcriptional
activator of several SM specific genes [13,29,30,31]. In wild-type
ureters at E14.5, we found that SOX9 and MYOCD proteins
were co-detected in the SMC progenitors of WT ureters
(Figure 3A–C), as supported by the absence of SMaA
(Figure 3D). One day later at E15.5, the SOX9 level decreased
and the protein was excluded from the MYOCD expression
domain (Figure 3E–G); SMaA was now detected (Figure 3H). At
E16.5, SOX9 was detected in the loose mesenchyme that will
mature into connective tissue but SOX9 was absent from the SM
layer (Figure S2H–J). In contrast to SOX9, expression of Tshz3
was maintained from E15.5 onwards in the SM layer ([11];
Figure S2 C, D, F, G). As the expression of SM genes depends on
the presence of the serum response factor (SRF), we confirmed
that SRF was expressed at E14.5 and E15.5 in ureteric
mesenchymal cells (Figure S2K–P). In the urogenital tract, the
initiation of SM development is first detected in the presumptive
bladder and 48 h later, it occurs in the developing ureter [28].
Accordingly, immunostaining of mouse embryonic urogenital
tracts at E13.5 showed Myocardin staining in the bladder but not
in the ureter (Figure S2 Q, R). This in vivo analysis temporally
delineates the multistep process of the SM progenitor cell
differentiation.
TSHZ3 and SOX9 repress the myogenic activity of
MYOCD
A large number of studies established that MYOCD activates
SM genes directly through an obligate interaction with SRF
[32,33]. Thus, we sought to analyse the consequence of the
expression of TSHZ3 and SOX9 on the MYOCD/SRF-mediated
transcriptional activation of SM-specific genes in more detail. This
analysis was performed in the C3H10T1/2 fibroblastic cell line,
Figure 6. TSHZ3 and SOX9 compete with SRF for binding to
MYOCD. (A–C) HEK293T cells were transfected with vectors encoding
HA-SRF, HA-SOX9, HA-TSHZ3, HA-TSHZ3-trunc with Flag-MYOCD or
control empty plasmid as indicated. HA-tagged proteins were identified
by their molecular weight. Flag-MYOCD was immunoprecipitated (IP)
from nuclear extracts of the transfected cells and co-precipitating HA-
tagged proteins were detected by Western blotting.
doi:10.1371/journal.pone.0063721.g006
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which represents a relevant cellular model for studying SM
differentiation [34,35]. Sox9 or Tshz3 expression plasmids were
transfected individually or in combination with or without Myocd
expression plasmid in 10T1/2 cells. Evaluation of mRNA levels of
SM genes by quantitative real-time PCR (qRT-PCR) showed that
forced expression of TSHZ3 and SOX9 significantly diminished
the MYOCD/SRF-mediated transcriptional activation of SM
genes (Figure 4A). qRT-PCR analysis showed that the relative
levels of exogenousMyocd mRNA were comparable in the different
conditions, indicating that the observed repression was not related
to variation of Myocd expression (Figure S3). Based on the above
findings, we examined the effect of TSHZ3 and SOX9 on the
luciferase activity of reporter plasmids containing the minimal
promoters of a series of SM specific genes. We found that TSHZ3
and SOX9 potently repressed MYOCD/SRF-mediated luciferase
activity of reporter plasmids (Figure 4B). We conclude that
TSHZ3 and SOX9 interfere with the transcriptional activity of
MYOCD/SRF.
TSHZ3 interacts with MYOCD
The regulation of SM gene expression depends on the
interaction of SRF with cofactors and the displacement of
MYOCD from SRF can lead to the repression of SM genes
[13,36,37]. We hypothesised that TSHZ3 and SOX9 modulate
the transcriptional activity of MYOCD/SRF by interacting with
either MYOCD or SRF. To test this hypothesis, we performed
GST pull-down and coimmunoprecipitation assays. As shown in
Figure 5A, TSHZ3 interacted efficiently with MYOCD. In
contrast, SRF neither bound to SOX9 nor to TSHZ3 (not
shown); and SOX9 did not bind to MYOCD (Figure S4A).
We mapped the MYOCD-binding domain of TSHZ3 in
coimmunoprecipitation and GST pull-down assays using truncat-
ed constructs of TSHZ3. GST pull-down experiments showed that
MYOCD interacts with the N-terminal half of TSHZ3 (Figure 5A
and Figure S4B). To investigate the interaction of MYOCD and
TSHZ3 further, we performed coimmunoprecipitation assays.
HEK cells were transfected with expression plasmids for the SM
isoform of MYOCD (Flag-tagged MYOCD-856, [22]), and
TSHZ3-HA. We verified that MYOCD and TSHZ3 transfected
proteins predominantly localized to the nucleus of HEK cells
(Figure S4C). Specific interaction of MYOCD and TSHZ3 was
observed by co-IP with anti-Flag antibody followed by immuno-
blotting with anti-HA (Figure 5B and Figure S4D). Co-IP assays
showed that N-TSHZ3-HA and a TSHZ3 truncated protein
lacking the three zinc finger domains (TSHZ3 dZNF-HA) bound
to MYOCD-Flag (Figure 5C, D). Co-IP experiments revealed, in
contrast, that a TSHZ3 N-terminal deletion mutant lacking
residues 1–182 (TSHZ3-trunc-HA) lost both the ability to interact
with MYOCD and to repress the transcriptional activity of
MYOCD/SRF (Figure 5, E, F). Thus, the ability of TSHZ3 to
inhibit SM gene promoter correlated with the ability to interact
with MYOCD and was probably specific for MYOCD activity, as
TSHZ3 did not affect SRF trans-activation properties (Figur-
e S4E).
TSHZ3 and SOX9 interfere with MYOCD/SRF complex
formation
As the displacement of MYOCD from SRF can lead to the
repression of SM genes, we analysed whether TSHZ3 and SOX9
could affect the interaction of MYOCD with SRF [37]. We tested
this hypothesis by performing co-IP experiments. We first
determined the effect of TSHZ3 and found that the amount of
immunoprecipitated SRF decreased with increasing amounts of
TSHZ3 (Figure 6A). In addition, we found that the TSHZ3-trunc
protein lacking the MYOCD interaction domain did not affect
SRF binding to MYOCD (Figure 6B), suggesting that the direct
interaction between TSHZ3 and MYOCD prevents the associa-
tion of SRF with MYOCD. We next analyzed the effect of both
SOX9 and TSHZ3 on MYOCD/SRF complex formation. We
found that MYOCD was less efficient to immunoprecipitate SRF.
In SOX9 transfected cells, SOX9-HA was detected in the
immunoprecipitate, probably via its interaction with TSHZ3
(Figure 6C). Together, these results suggest that the presence
SOX9 and TSHZ3 can displace MYOCD from SRF, and as a
consequence, prevents the activation of SM genes.
Prolonged expression of SOX9 in the ureteric
mesenchyme does not prevent initiation of Myocd
expression but reduces expression levels of SM genes
Our in vitro data suggest that MYOCD is displaced from SRF in
the presence of SOX9 and TSHZ3 (Figure 6C), and that
expression of SM genes correlates with the downregulation of
Sox9 in vivo (Figure 3 and 7A). If this was of functional importance,
prolonged expression of Sox9 should affect the transcriptional
activation of MYOCD/SRF target genes without affecting the
expression of Myocd (Figure 7B). To test this, Sox9 expression was
maintained in the ureteric mesenchyme beyond E14.5 using a
conditional Cre/loxP-based Sox9 misexpression approach [10],
and expression of MYOCD/SRF target genes was measured.
E16.5 ureters from wild-type and Tbx18Cre/+;HprtSox9/+ mice were
collected and the levels of Myocd and SM gene transcripts
measured by qRT-PCR. We found that prolonged expression of
Sox9 significantly affects SM gene but not Myocd expression
(Figure 7C), suggesting that down-regulation of Sox9 is important
to trigger the expression of SM genes and the progression of
myogenic program.
Discussion
Myocd encodes a transcriptional coactivator that physically
associates with the MADS-box transcription factor, SRF, to
promote myogenic differentiation. Expression and activity of
Myocd/MYOCD is tightly controlled in space and time by a
multitude of signaling pathways and transcriptional moieties in
different SMC programs. Here, we have shown that in the ureteric
mesenchyme the two transcription factors TSHZ3 and SOX9
control MYOCD transcriptional activity, thus, SMC differentia-
tion, by ternary complex formation. Together with the previous
Figure 7. Model of timing of SM differentiation in the developing ureter. (A) Activation of the expression of SM genes correlates with the
downregulation of Sox9. (B) In vivo and in vitro data suggest that prolonged expression of Sox9 affects the transcriptional activation of SM genes but
not the expression of Myocd. (C) Quantitative analysis of transcripts of Sox9, Myocd and SM markers in E16.5 wild-type and Tbx18Cre/+;HprtSox9/+
(prolonged Sox9) dissected ureters. mRNA transcripts were normalized to glyceraldehyde 3-phosphate dehydrogenase (Gadph) (n = 7, mean6 SEM). (D)
The upper panel shows the correlation between the status of ureteric mesenchymal cell differentiation, and the expression of the SM regulatory
factors Tshz3, Sox9 and Myocd. The middle panel schematizes the expression levels of these regulatory genes during ureter development. The bottom
panel summarizes the molecular interactions and the molecular switch that precedes the expression of SM genes. In the undifferentiated
mesenchyme Tshz3 and Sox9 are required for the expression of Myocd. SM progenitors express TSHZ3, SOX9 and MYOCD. Downregulation of SOX9
allows expression of SM genes, thus, a ‘‘functional switch’’ from embryonic ureteric tube to the contractile ureter.
doi:10.1371/journal.pone.0063721.g007
Timing the Ureteric Myogenic Program
PLOS ONE | www.plosone.org 10 May 2013 | Volume 8 | Issue 5 | e63721
findings that TSHZ3 and SOX9 are required for Myocd
expression, this points to a crucial and dynamic function of these
two transcription factors in ureteric SM development.
A TSHZ/SOX9/MYOCD pathway controls SM
differentiation of progenitor cells
The differentiation of ureteric mesenchyme into SMCs is
sensitive to extracellular cues. In response to SHH from the
ureteric epithelium, surrounding mesenchymal cells activate Bmp4
[8]. TSHZ3 and SOX9 are likely to act downstream of BMP4 to
trigger the initiation of the myogenic program through the
transcriptional activation of Myocd [10,11]. To date, a functional
requirement for Myocd or Srf has not been established, but the
absence of Myocd expression in Tshz3- and Sox9-mutant ureters,
that show perturbed SMC differentiation, argue for a key role for
Myocd in the initiation of the myogenic program [10,11]. However,
the precise nature of the molecular pathways regulating Myocd
expression in the ureter remain poorly described and the
regulatory regions responsible for transcriptional activation of
Myocd have not been identified [22,38]. In Sox9-deficient ureters,
the expression of Tshz3 is not affected [10], and in Tshz3-mutant
ureters Sox9 expression is unchanged (Figure S5), indicating that
Tshz3 and Sox9 do not regulate each other. Physical interaction
between TSHZ3 and SOX9 as identified in this study, may
provide a clue for an upstream module for transcriptional
activation of Myocd. This heterodimeric complex may directly
activate Myocd transcription, alternatively it may provide a
permissive environment for the expression of Myocd. Further
characterization of Tshz3- and Sox9-mutant ureters may contribute
to our understanding of the transcriptional regulation of Myocd in
visceral SMC progenitors and the initiation of their differentiation
program.
The results of this study indicate that TSHZ3 and SOX9
regulate the progression of the SM differentiation program by
controlling the activity of MYOCD. The following observations
support this conclusion. (1) TSHZ3 and SOX9 reduce the ability
of MYOCD to activate expression of endogenous SM genes, as
well as luciferase reporter gene controlled by SM gene promoter.
(2) TSHZ3 and SOX9 form a ternary complex with MYOCD that
strongly reduces the ability of MYOCD to interact with SRF. (3)
Prolonged expression of Sox9 prevents MYOCD to activate
expression of endogenous SM genes. (4) TSHZ3 interacts directly
with MYOCD and there is a positive correlation between the
domain of TSHZ3 required for interaction with MYOCD and
repression of SM gene expression. These data add to the notion
that regulation of MYOCD activity provides another layer in the
control mechanisms of SMC differentiation. They also explain
why both ablation and overexpression of Sox9 in ureteric
mesenchymal cells affect SMC differentiation.
Based on these results, we propose a mechanistic model on the
initiation and progression of ureteric SM differentiation by
TSHZ3 and SOX9 (Figure 7C). TSHZ3 and SOX9 regulate
the expression of Myocd, which is a critical step for the initiation of
the myogenic program. Then TSHZ3 and SOX9 form a ternary
complex with MYOCD, which prevents MYOCD from activating
SM specific genes. The subsequent down-regulation of Sox9
expression allows the interaction between MYOCD and SRF to
activate the expression of SM genes. Interestingly, analysis of Shh-
mutant ureters has led to the hypothesis that SM progenitors
require a signal for differentiation, suggesting that in absence of
this signal SM progenitors do not differentiate [8]. One possibility
could be that the differentiation signal triggers the downregulation
of Sox9 expression. In absence of the signal, inhibition of MYOCD
activity by TSHZ3 and SOX9 may maintain a progenitor-like
state. Clearly, identification of this signal through which down-
regulation of Sox9 occurs is critical and would represent a major
advance in understanding the mechanisms underpinning ureteric
SM differentiation.
Cellular and biochemical experiments suggest that despite the
presence of the potent activator MYOCD, TSHZ3 and SOX9
impair the activation of SM specific genes, favoring the
maintenance of a progenitor state. In vivo, there is a close
correlation between the downregulation of Sox9 and the initiation
of the expression of SRF/MYOCD target genes. Prolonged
expression of Sox9 clearly provided in vivo evidence for the
inhibitory role of Sox9 in visceral myogenesis. Of note, the
correlation between the downregulation of Sox9 and the mesen-
chymal cell differentiation has previously been described in
osteoblast differentiation [39]. In skeletal muscles, it has been
proposed that Tshz3 and Sox9 might be responsible for maintain-
ing myoblasts in an undifferentiated state and prevent differenti-
ation into myotubes. Notably, in the presence of TSHZ3 or
SOX9, MYOD is unable to activate the myogenin promoter
[40,41].
These data suggest that Tshz3 and Sox9 direct ureteric
mesenchymal cells to the visceral SM lineage but Sox9 inhibits
differentiation of SM progenitor cells into mature SM.
Similar strategies in vascular and visceral myogenic
programs
We identified a dynamic transcriptional network, in which
transcription factors are required in a first step to initiate the
expression of Myocd and in a second step to trigger the progression
of the myogenic program by controlling the activity of MYOCD.
This two-step mechanism bears similarity with a mechanism
previously described for vascular smooth and cardiac muscles,
where the FOXO4 factor participates in the transcriptional
activation of Myocd and FOXO4 can interact with and repress
the transcriptional activity of MYOCD [22,42]. It has been
proposed that the interaction between FOXO4 and MYOCD
might help to fine tune the potent transcriptional activity of
MYOCD [22]. The capacity of TSHZ3 to modulate the activity of
MYOCD/SRF suggests that in visceral SMC TSHZ3 might help
to fine-tune the transcriptional activity of MYOCD at late stages
of ureter development.
Based on current knowledge this model might not occur in other
context of visceral SM development. In the future, it would be
important to consider whether the combinatorial action of TSHZ3
and SOX9 could apply to other TSHZ and SOX factors.
Supporting Information
Figure S1 TSHZ3 and SOX9 form a complex in vivo and
in vitro. (A) GST-SOX9 or GST alone were incubated with N-
TSHZ3, TSHZ3fl, or C-TSHZ3 in vitro expressed in reticulocyte.
(B) HEK cells were transfected with Flag-tagged SOX9 and HA-
tagged TSHZ3. TSHZ3 proteins were immunoprecipitated using
anti-HA antibody, as indicated. Immunoprecipitated proteins
were identified by Western blotting using antibodies against the
HA and Flag epitopes.
(TIF)
Figure S2 Maintenance of TSHZ3 protein in ureteric
SM progenitors and SM cells, and loss of SOX9 detection
in SM cells at E16.5. (A–D) Transverse sections of proximal
ureters showing b-galactosidase immunostaining (brown), which
recapitulates TSHZ3 expression, and expression of myocardin by in
situ hybridization (purple signal) at E14.5 and E15.5. (E–J)
Detection of THSZ3 protein (green, F, G) contrasting with
Timing the Ureteric Myogenic Program
PLOS ONE | www.plosone.org 11 May 2013 | Volume 8 | Issue 5 | e63721
absence of SOX9 (red, I, J) in SM cells stained with the SM
marker: SMA (magenta, E, H) on transverse sections of ureters at
E16.5. (K–P) Detection of SRF (green, K, M, N, P) and SMA
(magenta, L, M, O, P) on transverse sections of ureters at E14.5
(K–M) and E15.5 (N–P). (Q, R) Expression of Myocardin in the
ureter and the bladder at E13.5. Q and R, Immunostaining for
Myocardin (red) and nuclei (DAPI, Blue). Myocd was not detected
in the ureteral mesenchyme (A), in contrast to the bladder (B).
Dotted line in A separates the epithelial layer and the
mesenchymal layer. Asterisk indicates the lumen of the ureter.
(TIF)
Figure S3 Myocd expression is stable. 10T1/2 cells were
cotransfected with the indicated constructs. 24 hours post
nucleofection, total RNA was harvested from cells and expression
levels of exogenous Myocd were measured by qRT-PCR.
(TIF)
Figure S4 TSHZ3 interacts with MYOCD. (A) HEK cells
were transfected with expression vectors encoding Flag-tagged
SOX9 and HA-tagged MYOCD. Cell lysates were incubated with
anti-Flag (SOX9) antibody, and the immunoprecipitates were
probed with anti-HA (MYOCD) or anti-Flag (SOX9) antibodies
by Western analysis. (B) Aliquots of in vitro translated 35S-labelled
full-length (TSHZ3 fl) and deletion mutants of TSHZ3 (N-
TSHZ3, C-TSHZ3) were incubated with glutathionne-Sepharose
beads loaded with bacterially expressed GST alone or GST-
MYOCD. The retained 35S-labeled TSHZ3 proteins were
separated on SDS-PAGE followed by autoradiography. 10% of
input (in) is shown on the left. In control experiments, no binding
of TSHZ3 proteins to the GST beads was observed. (C) TSHZ3-
HA (red, anti-HA epitope tag), N-TSHZ3-HA (red) and
MYOCD-Flag (green, anti-Flag epitope tag) localize to the
nucleus in HEK293T transfected cells. Cells were counterstained
with DAPI to detect nuclei. (D) HEK cells were transfected with
expression vectors encoding Flag-tagged MYOCD and HA-tagged
TSHZ3. Cell lysates were incubated with anti-HA (TSHZ3)
antibody, and the immunoprecipitates were probed with anti-HA
(TSHZ3) or anti-Flag (MYOCD) antibodies by Western analysis.
(E) 10T1/2 with indicated combination of expression constructs
and a luciferase reporter controlled by SMaA. Luciferase activity
was measured. SRF significantly activated SMA luciferase
promoter around 1,5 fold relative to the basal activity of SMA
promoter alone. This activation was unaffected by co-transfection
with TSHSZ3. An arbitrary value of 1 was assigned to the basal
activity of SMA promoter alone. (n = 12, mean 6 S.EM).
(TIF)
Figure S5 Expression of Sox9 is not affected in Tshz3
mutant ureters. (A, B) Sox9 expression in wild type ureter. (C,
D) Sox9 expression in Tshz3 mutant ureter.
(TIF)
Acknowledgments
We are thankful to Helen Skaer, Teddy Fauquier, Andreas Schedl and
Adrian Woolf for helpful discussions.
Author Contributions
Conceived and designed the experiments: AK LF. Performed the
experiments: EM XC RA CV AF AK LF. Analyzed the data: EM XC
RA CV AF AK LF. Contributed reagents/materials/analysis tools: EM
XC RA CV AF AK LF. Wrote the paper: EM XC RA CV AK LF.
References
1. Brenner-Anantharam A, Cebrian C, Guillaume R, Hurtado R, Sun TT, et al.
(2007) Tailbud-derived mesenchyme promotes urinary tract segmentation via
BMP4 signaling. Development 134: 1967–1975.
2. Cain JE, Hartwig S, Bertram JF, Rosenblum ND (2008) Bone morphogenetic
protein signaling in the developing kidney: present and future. Differentiation
76: 831–842.
3. Carroll TJ, Park JS, Hayashi S, Majumdar A, McMahon AP (2005) Wnt9b plays
a central role in the regulation of mesenchymal to epithelial transitions
underlying organogenesis of the mammalian urogenital system. Dev Cell 9: 283–
292.
4. Michos O, Goncalves A, Lopez-Rios J, Tiecke E, Naillat F, et al. (2007)
Reduction of BMP4 activity by gremlin 1 enables ureteric bud outgrowth and
GDNF/WNT11 feedback signalling during kidney branching morphogenesis.
Development 134: 2397–2405.
5. Miyazaki Y, Oshima K, Fogo A, Hogan BL, Ichikawa I (2000) Bone
morphogenetic protein 4 regulates the budding site and elongation of the
mouse ureter. J Clin Invest 105: 863–873.
6. Raatikainen-Ahokas A, Hytonen M, Tenhunen A, Sainio K, Sariola H (2000)
BMP-4 affects the differentiation of metanephric mesenchyme and reveals an
early anterior-posterior axis of the embryonic kidney. Dev Dyn 217: 146–158.
7. Wang GJ, Brenner-Anantharam A, Vaughan ED, Herzlinger D (2009)
Antagonism of BMP4 signaling disrupts smooth muscle investment of the ureter
and ureteropelvic junction. J Urol 181: 401–407.
8. Yu J, Carroll TJ, McMahon AP (2002) Sonic hedgehog regulates proliferation
and differentiation of mesenchymal cells in the mouse metanephric kidney.
Development 129: 5301–5312.
9. Airik R, Bussen M, Singh MK, Petry M, Kispert A (2006) Tbx18 regulates the
development of the ureteral mesenchyme. J Clin Invest 116: 663–674.
10. Airik R, Trowe MO, Foik A, Farin HF, Petry M, et al. (2010) Hydroureterne-
phrosis due to loss of Sox9-regulated smooth muscle cell differentiation of the
ureteric mesenchyme. Hum Mol Genet 19: 4918–4929.
11. Caubit X, Lye CM, Martin E, Core N, Long DA, et al. (2008) Teashirt 3 is
necessary for ureteral smooth muscle differentiation downstream of SHH and
BMP4. Development 135: 3301–3310.
12. Nie X, Sun J, Gordon RE, Cai CL, Xu PX (2010) SIX1 acts synergistically with
TBX18 in mediating ureteral smooth muscle formation. Development 137: 755–
765.
13. Wang D, Chang PS, Wang Z, Sutherland L, Richardson JA, et al. (2001)
Activation of cardiac gene expression by myocardin, a transcriptional cofactor
for serum response factor. Cell 105: 851–862.
14. Lye CM, Fasano L, Woolf AS (2010) Ureter myogenesis: putting Teashirt into
context. J Am Soc Nephrol 21: 24–30.
15. Reginensi A, Clarkson M, Neirijnck Y, Lu B, Ohyama T, et al. (2011) SOX9
controls epithelial branching by activating RET effector genes during kidney
development. Hum Mol Genet 20: 1143–1153.
16. dell’Agnola CA, Carmassi LM, Merlo D, Tadini B (1990) Duration and severity
of congenital hydronephrosis as a cause of smooth muscle deterioration in pyelo-
ureteral junction obstruction. Z Kinderchir 45: 286–290.
17. Gunn TR, Mora JD, Pease P (1995) Antenatal diagnosis of urinary tract
abnormalities by ultrasonography after 28 weeks’ gestation: incidence and
outcome. Am J Obstet Gynecol 172: 479–486.
18. Ismaili K, Hall M, Piepsz A, Wissing KM, Collier F, et al. (2006) Primary
vesicoureteral reflux detected in neonates with a history of fetal renal pelvis
dilatation: a prospective clinical and imaging study. J Pediatr 148: 222–227.
19. Zhang PL, Peters CA, Rosen S (2000) Ureteropelvic junction obstruction:
morphological and clinical studies. Pediatr Nephrol 14: 820–826.
20. Faralli H, Martin E, Core N, Liu QC, Filippi P, et al. (2011) Teashirt-3, a novel
regulator of muscle differentiation, associates with BRG1-associated factor 57
(BAF57) to inhibit myogenin gene expression. The Journal of biological
chemistry 286: 23498–23510.
21. Caubit X, Tiveron MC, Cremer H, Fasano L (2005) Expression patterns of the
three Teashirt-related genes define specific boundaries in the developing and
postnatal mouse forebrain. J Comp Neurol 486: 76–88.
22. Creemers EE, Sutherland LB, McAnally J, Richardson JA, Olson EN (2006)
Myocardin is a direct transcriptional target of Mef2, Tead and Foxo proteins
during cardiovascular development. Development 133: 4245–4256.
23. Iwanaga Y, Kihara Y, Takenaka H, Kita T (2006) Down-regulation of cardiac
apelin system in hypertrophied and failing hearts: Possible role of angiotensin II-
angiotensin type 1 receptor system. J Mol Cell Cardiol 41: 798–806.
24. Gallet A, Angelats C, Kerridge S, Therond PP (2000) Cubitus interruptus-
independent transduction of the Hedgehog signal in Drosophila. Development
127: 5509–5522.
25. Kajiwara Y, Akram A, Katsel P, Haroutunian V, Schmeidler J, et al. (2009)
FE65 binds Teashirt, inhibiting expression of the primate-specific caspase-4.
PLoS One 4: e5071.
26. Onai T, Matsuo-Takasaki M, Inomata H, Aramaki T, Matsumura M, et al.
(2007) XTsh3 is an essential enhancing factor of canonical Wnt signaling in
Xenopus axial determination. EMBO J 26: 2350–2360.
27. Taghli-Lamallem O, Gallet A, Leroy F, Malapert P, Vola C, et al. (2007) Direct
interaction between Teashirt and Sex combs reduced proteins, via Tsh’s acidic
Timing the Ureteric Myogenic Program
PLOS ONE | www.plosone.org 12 May 2013 | Volume 8 | Issue 5 | e63721
domain, is essential for specifying the identity of the prothorax in Drosophila.
Dev Biol 307: 142–151.
28. McHugh KM (1995) Molecular analysis of smooth muscle development in the
mouse. Dev Dyn 204: 278–290.
29. Chen J, Kitchen CM, Streb JW, Miano JM (2002) Myocardin: a component of a
molecular switch for smooth muscle differentiation. Journal of molecular and
cellular cardiology 34: 1345–1356.
30. Huang J, Cheng L, Li J, Chen M, Zhou D, et al. (2008) Myocardin regulates
expression of contractile genes in smooth muscle cells and is required for closure
of the ductus arteriosus in mice. J Clin Invest 118: 515–525.
31. Li S, Wang DZ, Wang Z, Richardson JA, Olson EN (2003) The serum response
factor coactivator myocardin is required for vascular smooth muscle develop-
ment. Proc Natl Acad Sci U S A 100: 9366–9370.
32. Wang DZ, Li S, Hockemeyer D, Sutherland L, Wang Z, et al. (2002)
Potentiation of serum response factor activity by a family of myocardin-related
transcription factors. Proc Natl Acad Sci U S A 99: 14855–14860.
33. Wang Z, Wang DZ, Pipes GC, Olson EN (2003) Myocardin is a master
regulator of smooth muscle gene expression. Proc Natl Acad Sci U S A 100:
7129–7134.
34. Hirschi KK, Rohovsky SA, D’Amore PA (1998) PDGF, TGF-beta, and
heterotypic cell-cell interactions mediate endothelial cell-induced recruitment of
10T1/2 cells and their differentiation to a smooth muscle fate. J Cell Biol 141:
805–814.
35. Zhou J, Herring BP (2005) Mechanisms responsible for the promoter-specific
effects of myocardin. J Biol Chem 280: 10861–10869.
36. Du KL, Ip HS, Li J, Chen M, Dandre F, et al. (2003) Myocardin is a critical
serum response factor cofactor in the transcriptional program regulating smooth
muscle cell differentiation. Molecular and Cellular Biology 23: 2425–2437.
37. Wang Z, Wang DZ, Hockemeyer D, McAnally J, Nordheim A, et al. (2004)
Myocardin and ternary complex factors compete for SRF to control smooth
muscle gene expression. Nature 428: 185–189.
38. Zacharias WJ, Madison BB, Kretovich KE, Walton KD, Richards N, et al.
(2011) Hedgehog signaling controls homeostasis of adult intestinal smooth
muscle. Dev Biol.
39. Karsenty G (2008) Transcriptional control of skeletogenesis. Annu Rev
Genomics Hum Genet 9: 183–196.
40. Schmidt K, Glaser G, Wernig A, Wegner M, Rosorius O (2003) Sox8 is a
specific marker for muscle satellite cells and inhibits myogenesis. J Biol Chem
278: 29769–29775.
41. Faralli H, Martin E, Core N, Liu QC, Filippi P, et al. (2011) Teashirt-3, a novel
regulator of muscle differentiation, associates with BRG-1 associated factor 57
(BAF57) to inhibit myogenin gene expression. J Biol Chem.
42. Liu ZP, Wang Z, Yanagisawa H, Olson EN (2005) Phenotypic modulation of
smooth muscle cells through interaction of Foxo4 and myocardin. Dev Cell 9:
261–270.
Timing the Ureteric Myogenic Program
PLOS ONE | www.plosone.org 13 May 2013 | Volume 8 | Issue 5 | e63721
